Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

Por Chan, Jennifer A., Mayer, Robert J., Jackson, Nadine, Malinowski, Paige, Regan, Eileen, Kulke, Matthew H.
Publicado em 2013

Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors

Por Chan, Jennifer A., Ryan, David P., Zhu, Andrew X., Abrams, Thomas A, Wolpin, Brian M, Malinowski, Paige, Regan, Eileen M, Fuchs, Charles S., Kulke, Matthew H.
Publicado no Endocr Relat Cancer (2012)

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

Por Phan, Alexandria T, Halperin, Daniel M, Chan, Jennifer A, Fogelman, David R, Hess, Kenneth R, Malinowski, Paige, Regan, Eileen, Ng, Chaan S, Yao, James C, Kulke, Matthew H
Publicado no Lancet Oncol (2015)